Par Drugs and Chemicals (NSE:PAR) EPS (Basic): ₹10.65 (TTM As of Mar. 2026)


NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
77 GF Score
Price ₹91.00
GF Value ₹207.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals EPS (Basic)?

Par Drugs and Chemicals NSE:PAR -1.80% 77 EPS (Basic) is ₹10.65 as of Mar. 2026. GuruFocus rates NSE:PAR with a GF Score™ of 77/100 and a GF Value™ of ₹207.62 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Par Drugs and Chemicals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹0.69. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10.65.

Par Drugs and Chemicals's EPS (Diluted) for the three months ended in Mar. 2026 was ₹0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10.65.

Par Drugs and Chemicals's EPS without NRI for the three months ended in Mar. 2026 was ₹0.69. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 10.65.

During the past 12 months, Par Drugs and Chemicals's average EPS without NRIGrowth Rate was -1.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 5.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Par Drugs and Chemicals's highest 3-Year average EPS without NRI Growth Rate was 88.70% per year. The lowest was 5.30% per year. And the median was 33.30% per year.

Par Drugs and Chemicals  (NSE:PAR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Par Drugs and Chemicals EPS (Basic) Related Terms

Par Drugs and Chemicals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals EPS (Basic) Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.49 9.21 11.78 10.86 10.65

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 2.70 3.36 3.90 0.69
NSE:PAR
77GF Score
Par Drugs and Chemicals Ltd NSE:PAR
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Par Drugs and Chemicals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Par Drugs and Chemicals's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(131.086-0)/12.309
=10.65

Par Drugs and Chemicals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(8.536-0)/12.371
=0.69

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹10.65 mean?
Par Drugs and Chemicals (NSE:PAR) has a EPS (Basic) of ₹10.65 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Par Drugs and Chemicals and its competitors.
Is Par Drugs and Chemicals' EPS (Basic) too high?
Par Drugs and Chemicals' current EPS (Basic) is ₹10.65. Overall, Par Drugs and Chemicals has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' EPS (Basic) compare to ZTS?
Par Drugs and Chemicals' EPS (Basic) of ₹10.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Par Drugs and Chemicals and its competitors. Par Drugs and Chemicals's current EPS (Basic) is ₹10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.62, compared to a current price of ₹91.00 — trading 56.2% below its estimated fair value. The current EPS (Basic) is ₹10.65. Par Drugs and Chemicals' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current EPS (Basic) is ₹10.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹91.00 is trading 56.2% below its estimated GF Value™ of ₹207.62. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • EPS (Basic): ₹10.65
  • GF Value™: ₹207.62 vs. price of ₹91.00 (56.2% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
77GF Score

Get the complete analysis for NSE:PAR

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.00
Price
₹207.62
GF Value